Vice President, Investor Relations & Corporate Affairs
Aliso Viejo, CA – October 28, 2026 –Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:
Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis.
U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year- over-year.
Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year- over-year.
Gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026.
Diluted earnings per share (EPS) of $0.03 and non-GAAP diluted EPS of $0.47 in Q3 2026.
Cash and cash equivalents, short-term investments, and restricted cash of $339.8 million at the end of Q3 2026, an increase of $50.5 million compared to $289.3 million at the end of Q2 2026.
Raised 2026 net sales guidance to $775 million to $785 million, compared to $680 million to $700 million previously.
“Our record third quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers iniDose TRandEpioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Net sales in the third quarter of 2026 of $211.0 million increased 58% on a reported and constant currency basis, compared to $133.5 million in the same period in 2025.
Gross margin for the third quarter of 2026 was approximately 85%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the third quarter of 2026 was approximately 88%, compared to approximately 84% in the same period in 2025.
Selling, general and administrative (SG&A) expenses for the third quarter of 2026 increased 58% to $130.9 million, compared to $83.0 million in the same period in 2025. Non-GAAP SG&A expenses for the third quarter of 2026 increased 32% to $109.7 million, compared to $83.2 million in the same period in 2025.
GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2026 increased 26% to $48.1 million, compared to $38.1 million in the same period in 2025. 1 Income from operations in the third quarter of 2026 was $0.8 million, compared to operating loss of $16.4 million in the third quarter of 2025. Non-GAAP income from operations in the third quarter of 2026 was $27.3 million, compared to non- GAAP operating loss of $9.3 million in the third quarter of 2025.
Net income in the third quarter of 2026 was $2.0 million, or $0.03 per diluted share, compared to net loss of $16.2 million, or ($0.28) per diluted share, in the third quarter of 2025. Non-GAAP net income in the third quarter of 2026 was $28.5 million, or $0.47 per diluted share, compared to non-GAAP net loss of $9.2 million, or ($0.16) per diluted share, in the third quarter of 2025.
The company ended the third quarter of 2026 with approximately $339.8 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.
The company expects 2026 net sales to be in the range of $775 million to $785 million based on the latest foreign currency exchange rates.
The company expects preliminary 2027 net sales to be $1 billion based on the latest foreign currency exchange rates.
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website athttp://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 517868366. A replay of the webcast will be archived on the company’s website following completion of the call.
The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities foriDose®TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, 2 dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize ouriDose TRandEpioxatherapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our products; the potential for misuse of our products; our ability to manage our growth and meet customer demand; the success of our acquisitions, collaborations, in licensing agreements, joint ventures, alliances or partnerships with third parties; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; risks related to the implementation of artificial intelligence and machine learning technologies; the availability of net operating loss tax carryforwards; changes to domestic or foreign healthcare laws or trade policies, which could impact our profitability; the high cost of regulatory compliance, including the requirements of participation in federal healthcare programs such as Medicare and Medicaid and regulations for the approval and sale and marketing of our products and of our manufacturing processes; risks related to securing or maintaining adequate coverage or reimbursement by government or third-party payors the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; and our ability to protect, and the expense and time-consuming nature of protecting, our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to file on or before November 9, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. 3 Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non- GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis. 4 GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except per share amounts)
5 GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par values)
September 30, Assets 2026 December 31, Current assets: (unaudited) 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 162,327 $ 90,813 equivalents Short-term 174,372 187,947 investments Accounts 150,004 108,608 receivable, net Inventory 61,032 63,564 Prepaid expenses and 31,915 24,052 other current assets Total current 579,650 474,984 assets Restricted cash 3,115 3,834 Property and 112,068 113,253 equipment, net Operating lease right-of-use 30,795 31,527 asset Finance lease right-of-use 37,594 39,404 asset Intangible 121,261 141,916 assets, net Goodwill 66,710 66,710 Deposits and 28,336 21,859 other assets Total assets $ 979,529 $ 893,487 Liabilities and stockholders' equity Current liabilities: Accounts $ 24,407 $ 24,624 payable Accrued 102,319 76,651 liabilities Total current 126,726 101,275 liabilities Operating lease 35,057 35,767 liability Finance lease 66,926 68,109 liability Deferred tax 441 441 liability, net Other 33,105 31,740 liabilities Total 262,255 237,332 liabilities Stockholders' equity: Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued - - and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.001 par value; 150,000 shares authorized; 59,196 and 57,539 shares issued 59 58 and 59,168 and 57,511 shares outstanding at September 30, 2026 and December 31, 2025, respectively Additional 1,684,829 1,586,056 paid-in capital Accumulated other 1,790 3,303 comprehensive income Accumulated (969,272 ) (933,130 ) deficit Less treasury stock (28 shares as of September 30, (132 ) (132 ) 2026 and December 31, 2025) Total stockholders' 717,274 656,155 equity Total liabilities and $ 979,529 $ 893,487 stockholders' equity
6 GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited)
(A) • Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $4.8 million in Q3 2026 and $5.5 million in Q3 2025. • Mobius acquisition- related amortization expense of developed intellectual property of $0.5 million in Q3 2026 and Q3 2025, respectively. (B) • Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million. (C) • Expenses of $5.9 million related to the Company’s trade secrets litigation and other litigation matters. • Expenses of $14.1 million related to the resolution agreement with the Regents of the University of California. • Expenses of $0.8 million associated with the integration of a major system. (D) • Mobius contingent consideration fair value adjustments of $0.4 million in Q3 2026 and ($0.2) million in Q3 2025. (E) • Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025. 7 GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited)
(A) • Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $17.8 million year-to-date Q3 2026 and $16.6 million year-to-date Q3 2025. • Mobius acquisition-related amortization expense of developed intellectual property of $1.5 million year-to-date Q3 2026 and $0.7 million year-to-date Q3 2025. (B) • Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million. (C) • Expenses of $9.9 million related to the Company’s trade secrets litigation and other litigation matters. • Expenses of $14.1 million related to the resolution agreement with the Regents of the University of California. • Expenses of $1.2 million associated with the integration of a major system. • Provision for doubtful accounts related to the overpayment of prior period payroll withholdings of $0.7 million. (D) • Mobius contingent consideration fair value adjustments of $0.4 million year-to-date Q3 2026 and ($0.2) million year-to-date Q3 2025. • Mobius acquisition-related transaction expense of $0.3 million year-to-date Q3 2025. (E) • Interest expense related to the untimely payment of prior period payroll withholdings (F) • Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025. (G) • Year-to-date Q3 2026 non-GAAP diluted weighted-average shares reflect the dilution effect from outstanding stock options, unvested restricted stock units, performance-based equity awards, and employee stock purchase program option shares under the treasury stock method. 8
(1) Operational growth excludes the effect of translational currency (2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates 9
Full text with the tables
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact:
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
[email protected]
Glaukos Announces Third Quarter 2026 Financial Results
Aliso Viejo, CA – October 28, 2026 –Glaukos Corporation (NYSE: GKOS), an
ophthalmic pharmaceutical and medical technology company focused on novel
therapies for the treatment of glaucoma, corneal disorders, and retinal
diseases, today announced financial results for the third quarter ended
September 30, 2026. Key highlights include:
Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a
reported and constant currency basis.
U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-
over-year.
Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-
over-year.
Gross margin of approximately 85% and non-GAAP gross margin of approximately 88%
in Q3 2026.
Net income of $2.0 million and non-GAAP net income of $28.5 million in Q3 2026.
Diluted earnings per share (EPS) of $0.03 and non-GAAP diluted EPS of $0.47 in
Q3 2026.
Cash and cash equivalents, short-term investments, and restricted cash of $339.8
million at the end of Q3 2026, an increase of $50.5 million compared to $289.3
million at the end of Q2 2026.
Raised 2026 net sales guidance to $775 million to $785 million, compared to $680
million to $700 million previously.
Introduced preliminary 2027 net sales guidance of $1 billion.
“Our record third quarter results reflect successful global execution across our
key global commercial and development priorities, leaving us well positioned to
sustain our strong growth momentum driven by two transformational growth drivers
iniDose TRandEpioxa,” said Thomas Burns, Glaukos chairman and chief executive
officer. “We continue to successfully advance our robust pipeline of novel,
dropless platform technologies designed to meaningfully advance the standard of
care and improve outcomes for patients suffering from chronic eye diseases.”
Third Quarter 2026 Financial Results
Net sales in the third quarter of 2026 of $211.0 million increased 58% on a
reported and constant currency basis, compared to $133.5 million in the same
period in 2025.
Gross margin for the third quarter of 2026 was approximately 85%, compared to
approximately 78% in the same period in 2025. Non-GAAP gross margin for the
third quarter of 2026 was approximately 88%, compared to approximately 84% in
the same period in 2025.
Selling, general and administrative (SG&A) expenses for the third quarter of
2026 increased 58% to $130.9 million, compared to $83.0 million in the same
period in 2025. Non-GAAP SG&A expenses for the third quarter of 2026 increased
32% to $109.7 million, compared to $83.2 million in the same period in 2025.
GAAP and non-GAAP research and development (R&D) expenses for the third quarter
of 2026 increased 26% to $48.1 million, compared to $38.1 million in the same
period in 2025.
1
Income from operations in the third quarter of 2026 was $0.8 million, compared
to operating loss of $16.4 million in the third quarter of 2025. Non-GAAP income
from operations in the third quarter of 2026 was $27.3 million, compared to non-
GAAP operating loss of $9.3 million in the third quarter of 2025.
Net income in the third quarter of 2026 was $2.0 million, or $0.03 per diluted
share, compared to net loss of $16.2 million, or ($0.28) per diluted share, in
the third quarter of 2025. Non-GAAP net income in the third quarter of 2026 was
$28.5 million, or $0.47 per diluted share, compared to non-GAAP net loss of $9.2
million, or ($0.16) per diluted share, in the third quarter of 2025.
The company ended the third quarter of 2026 with approximately $339.8 million in
cash and cash equivalents, short-term investments, and restricted cash, and no
debt.
2026 Revenue Guidance
The company expects 2026 net sales to be in the range of $775 million to $785
million based on the latest foreign currency exchange rates.
2027 Preliminary Revenue Guidance
The company expects preliminary 2027 net sales to be $1 billion based on the
latest foreign currency exchange rates.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30
p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information
about the company’s financial outlook. A link to the webcast is available on the
company’s website athttp://investors.glaukos.com. To participate in the
conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international)
and enter Conference ID 517868366. A replay of the webcast will be archived on
the company’s website following completion of the call.
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the
“Financials & Filings – Quarterly Results” section titled “Quarterly Summary.”
This Quarterly Summary document is designed to provide the investment community
with a summarized and easily accessible reference document that details the key
facts associated with the quarter, the state of the company’s business
objectives and strategies, and any forward statements or guidance the company
may make. This document is provided alongside the company’s earnings press
release and is designed to be read by investors before the regularly scheduled
quarterly conference call. It is the company’s goal that this format will make
its quarterly earnings process more efficient and impactful for the investment
community.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology
company focused on developing and commercializing novel therapies for the
treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first
developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS device
commercially in 2012. In 2024, Glaukos commenced commercial launch activities
foriDose®TR, a first-of-its-kind, long-duration, intracameral procedural
pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for
extended periods of time. Glaukos also markets the only FDA-approved corneal
cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for
the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos
continues to successfully develop and advance a robust pipeline of novel,
2
dropless platform technologies designed to meaningfully advance the standard of
care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of
federal securities laws. All statements other than statements of historical
facts included in this press release that address activities, events or
developments that we expect, believe or anticipate will or may occur in the
future are forward-looking statements. These statements are based on
management’s current expectations, assumptions, estimates and beliefs. Although
we believe that we have a reasonable basis for forward-looking statements
contained herein, we caution you that they are based on current expectations
about future events affecting us and are subject to risks, uncertainties and
factors relating to our operations and business environment, all of which are
difficult to predict and many of which are beyond our control, that may cause
our actual results to differ materially from those expressed or implied by
forward-looking statements in this press release. These potential risks and
uncertainties that could cause actual results to differ materially from those
described in forward-looking statements include, without limitation, our ability
to successfully commercialize ouriDose TRandEpioxatherapies; the impact of
general macroeconomic conditions including foreign currency fluctuations and
future public health crises; supply and/or manufacturing disruptions, including
those impacting our principal revenue-producing products, including the risk of
recalls or serious safety issues with our products; our ability to achieve or
sustain profitability, generate sales of our commercialized products and develop
and commercialize additional products; risks associated with our international
operations; our ability to meet our customers’ expectations for the quality or
delivery of our products; the potential for misuse of our products; our ability
to manage our growth and meet customer demand; the success of our acquisitions,
collaborations, in licensing agreements, joint ventures, alliances or
partnerships with third parties; our ability to protect our information systems
against cyber threats and cybersecurity incidents, and to comply with state,
federal and foreign data privacy laws and regulations; risks related to the
implementation of artificial intelligence and machine learning technologies; the
availability of net operating loss tax carryforwards; changes to domestic or
foreign healthcare laws or trade policies, which could impact our profitability;
the high cost of regulatory compliance, including the requirements of
participation in federal healthcare programs such as Medicare and Medicaid and
regulations for the approval and sale and marketing of our products and of our
manufacturing processes; risks related to securing or maintaining adequate
coverage or reimbursement by government or third-party payors the lengthy and
expensive clinical trial process and the uncertainty of timing and outcomes from
any particular clinical trial or regulatory approval processes; and our ability
to protect, and the expense and time-consuming nature of protecting, our
intellectual property against third parties and competitors and the impact of
any claims against us for infringement or misappropriation of third party
intellectual property rights and any related litigation. These and other known
risks, uncertainties and factors are described in detail under the caption “Risk
Factors” and elsewhere in our filings with the Securities and Exchange
Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2026, which was filed with the SEC on July 29, 2026, and our
Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we
expect to file on or before November 9, 2026. Our filings with the SEC are
available in the Investor Section of our website at www.glaukos.com or at
www.sec.gov. In addition, information about the risks and benefits of our
products is available on our website at www.glaukos.com. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on the forward-looking statements in this press release, which
speak only as of the date hereof. We do not undertake any obligation to update,
amend or clarify these forward-looking statements whether as a result of new
information, future events or otherwise, except as may be required under
applicable securities law.
3
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with
Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-
GAAP historical financial measures. Management makes adjustments to the GAAP
measures for items (both charges and gains) that (a) do not reflect the core
operational activities of the Company, (b) are commonly adjusted within the
Company's industry to enhance comparability of the Company's financial results
with those of its peer group, or (c) are inconsistent in amount or frequency
between periods (albeit such items are monitored and controlled with equal
diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses
the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the
Non-GAAP Purposes, including external acquisition-related costs incurred to
effect a business combination; amortization of intangible assets acquired in a
business combination, asset purchase transaction or other contractual
relationship; impairment of goodwill and intangible assets; certain in-process
R&D charges; fair value adjustments to contingent consideration liabilities and
pre-acquisition contingencies arising from a business combination; integration
and transition costs related to business combinations; fair market value
adjustments to inventories acquired in a business combination or asset purchase
transaction; restructuring charges, duplicative operating expenses, or asset
write-offs (or reversals) associated with exiting or significantly downsizing a
business; unusual non-recurring expenses associated with inventory write-downs;
gain or loss from the sale of a business; gain or loss on the mark-to-market
adjustment, impairment, or sale of long-term investments; mark-to-market
adjustments on derivative instruments that hedge income or expense exposures in
a future period; significant legal litigation costs and/or settlement expenses
or proceeds; legal and other associated expenses that are both unusual and
significant related to governmental or internal inquiries; expenses,
acceleration of amortization of debt issuance costs and gain or loss on debt
extinguishment associated with the exchange or redemption of convertible senior
notes; significant discrete income and other tax adjustments related to
transactions as well as changes in estimated acquisition-date tax effects
associated with business combinations, and the impact from implementation of tax
law changes and settlements; and any other adjustment that is determined to be
appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP
Reconciliations” for a reconciliation of each non-GAAP measure presented to the
comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency
exchange rates, the Company also presents certain net sales information on a
constant currency basis, which represents the outcome that would have resulted
had exchange rates in the current period been the same as the average exchange
rates in effect in the comparable prior period. See “Reported Sales vs. Prior
Periods” for a presentation of certain net sales information on a reported, GAAP
and a constant currency basis.
4
GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except per share amounts)
Three Nine
Mont… Mon…
Ended Sept… End… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 211,… $ 133,… $ 547,… $ 364…
sal…
Cost
of 31,1… 28,8… 98,5… 80,…
sal…
Gro… 179,… 104,… 448,… 284…
pro…
Ope…
exp…
Sel…
gen… 130,… 82,9… 339,… 237…
and
adm…
Res…
and 48,0… 38,0… 143,… 106…
dev…
Acq…
in-…
res… - - 1,500 -
and
dev…
Tot…
ope… 179,… 121,… 484,… 344…
exp…
Inc…
(lo… 828 (16,… ) (36,… ) (59… )
from
ope…
Non…
inc…
(ex…
Int… 2,493 2,552 7,203 8,2…
inc…
Int… (1,0… ) (1,1… ) (3,6… ) (3,… )
exp…
Oth…
inc… 87 (1,0… ) (1,9… ) 1,7…
(ex…
net
Tot…
non… 1,493 368 1,596 6,5…
inc…
Inc…
(lo… 2,321 (15,… ) (34,… ) (53… )
bef…
tax…
Inc…
tax 303 234 1,443 808
pro…
Net
inc… $ 2,018 $ (16,… ) $ (36,… ) $ (54… )
(lo…
Bas…
net
inc… $ 0.03 $ (0.28 ) $ (0.62 ) $ (0.… )
(lo…
per
sha…
Dil…
net
inc… $ 0.03 $ (0.28 ) $ (0.62 ) $ (0.… )
(lo…
per
sha…
Wei…
sha…
out…
used
to
com… 59,1… 57,3… 58,6… 57,…
bas…
net
inc…
(lo…
per
sha…
Wei…
sha…
out…
used
to
com… 61,1… 57,3… 58,6… 57,…
dil…
net
inc…
(lo…
per
sha…
5
GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except
par values)
September 30,
Assets 2026 December 31,
Current assets: (unaudited) 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 162,327 $ 90,813
equivalents
Short-term 174,372 187,947
investments
Accounts 150,004 108,608
receivable, net
Inventory 61,032 63,564
Prepaid
expenses and 31,915 24,052
other current
assets
Total current 579,650 474,984
assets
Restricted cash 3,115 3,834
Property and 112,068 113,253
equipment, net
Operating lease
right-of-use 30,795 31,527
asset
Finance lease
right-of-use 37,594 39,404
asset
Intangible 121,261 141,916
assets, net
Goodwill 66,710 66,710
Deposits and 28,336 21,859
other assets
Total assets $ 979,529 $ 893,487
Liabilities and
stockholders'
equity
Current
liabilities:
Accounts $ 24,407 $ 24,624
payable
Accrued 102,319 76,651
liabilities
Total current 126,726 101,275
liabilities
Operating lease 35,057 35,767
liability
Finance lease 66,926 68,109
liability
Deferred tax 441 441
liability, net
Other 33,105 31,740
liabilities
Total 262,255 237,332
liabilities
Stockholders'
equity:
Preferred
stock, $0.001
par value;
5,000 shares
authorized; no
shares issued - -
and outstanding
as of September
30, 2026 and
December 31,
2025
Common stock,
$0.001 par
value; 150,000
shares
authorized;
59,196
and 57,539
shares issued 59 58
and 59,168 and
57,511 shares
outstanding at
September 30,
2026 and
December 31,
2025,
respectively
Additional 1,684,829 1,586,056
paid-in capital
Accumulated
other 1,790 3,303
comprehensive
income
Accumulated (969,272 ) (933,130 )
deficit
Less treasury
stock (28
shares as of
September 30, (132 ) (132 )
2026 and
December 31,
2025)
Total
stockholders' 717,274 656,155
equity
Total
liabilities and $ 979,529 $ 893,487
stockholders'
equity
6
GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per
share amounts and percentage data) (unaudited)
… Q3
… 2…
… … N… G… A… …
──────────────────────────────────────────────────────────────────────────────
… -…
… $ 3… $ (… ) … $ … $ … $ … ) (B $ 2…
…
… 8… % 2… % … % … % … % 8… %
…
…
…
…
… $ 1… $ (… ) … $ … $ … $ … -D $ 8…
…
…
…
… $ 8… $ 2… $ … $ … ) $ … $ (… )
…
…
…
… $ 2… $ 2… … $ … $ … ) $ … -E $ (… )
…
…
…
… $ 0… $ 0… $ … $ … ) $ … $ (… )
…
…
…
…
…
… $ 0… $ 0… $ … $ … ) $ … $ (… )
…
…
…
…
…
…
…
…
… 5… … … 5…
…
…
…
…
…
…
…
…
…
…
…
… 6… … … 5…
…
…
…
…
…
…
(A) • Cost of sales adjustment related to amortization of developed technology
intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of
$4.8 million in Q3 2026 and $5.5 million in Q3 2025. • Mobius acquisition-
related amortization expense of developed intellectual property of $0.5 million
in Q3 2026 and Q3 2025, respectively. (B) • Non-recurring, non-cash charge
related to the write-down of certain inventory of $1.3 million. (C) • Expenses
of $5.9 million related to the Company’s trade secrets litigation and other
litigation matters. • Expenses of $14.1 million related to the resolution
agreement with the Regents of the University of California. • Expenses of $0.8
million associated with the integration of a major system. (D) • Mobius
contingent consideration fair value adjustments of $0.4 million in Q3 2026 and
($0.2) million in Q3 2025. (E) • Includes total tax effect for non-GAAP pre-tax
adjustments. For non-GAAP adjustments associated with the U.S., the tax effect
is $0 given the Company's U.S. taxable loss positions in both 2026 and 2025.
7
GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per
share amounts and percentage data) (unaudited)
… Y…
… Q3
… 2…
… … N… G… A… …
──────────────────────────────────────────────────────────────────────────────
… -…
… $ 9… $ (… ) … $ … $ … $ … ) (B $ 6…
…
… 8… % 3… % … % … % … % 8… %
…
…
…
…
… $ 3… $ (… ) … $ … $ … $ … ) -D $ 2…
…
…
…
… $ (… ) $ 4… $ … $ … ) $ … $ (… )
…
…
…
…
…
… $ (… ) $ 3… … $ … ) $ … ) $ - $ (… )
…
…
… $ (… ) $ 4… … $ … $ … ) $ … -F $ (… )
…
…
…
… $ (… ) $ 0… $ … $ … ) $ … $ (… )
…
…
…
…
…
… $ (… ) $ 0… $ … $ … ) $ … $ (… )
…
…
…
…
…
…
…
…
… 5… … … 5…
…
…
…
…
…
…
…
…
…
…
…
…
… 5… … … 5…
…
…
…
…
…
…
(A) • Cost of sales adjustment related to amortization of developed technology
intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of
$17.8 million year-to-date Q3 2026 and $16.6 million year-to-date Q3 2025. •
Mobius acquisition-related amortization expense of developed intellectual
property of $1.5 million year-to-date Q3 2026 and $0.7 million year-to-date Q3
2025. (B) • Non-recurring, non-cash charge related to the write-down of certain
inventory of $1.3 million. (C) • Expenses of $9.9 million related to the
Company’s trade secrets litigation and other litigation matters. • Expenses of
$14.1 million related to the resolution agreement with the Regents of the
University of California. • Expenses of $1.2 million associated with the
integration of a major system. • Provision for doubtful accounts related to the
overpayment of prior period payroll withholdings of $0.7 million. (D) • Mobius
contingent consideration fair value adjustments of $0.4 million year-to-date Q3
2026 and ($0.2) million year-to-date Q3 2025. • Mobius acquisition-related
transaction expense of $0.3 million year-to-date Q3 2025. (E) • Interest expense
related to the untimely payment of prior period payroll withholdings (F) •
Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP
adjustments associated with the U.S., the tax effect is $0 given the Company's
U.S. taxable loss positions in both 2026 and 2025. (G) • Year-to-date Q3 2026
non-GAAP diluted weighted-average shares reflect the dilution effect from
outstanding stock options, unvested restricted stock units, performance-based
equity awards, and employee stock purchase program option shares under the
treasury stock method.
8
…
…
…
… Y… …
… P… …
… 3Q 3Q 2Q C… O… C… … … …
… 2… 2… 2… R… (… (… … … …
──────────────────────────────────────────────────────────────────────────────
… $ 3… $ … $ … … % … % -… … … …
…
…
… $ 2… $ … $ … … % … % -… 1… % 1… % …
…
(1) Operational growth excludes the effect of translational currency (2)
Calculated by converting the current period numbers using the prior period’s
average foreign exchange rates
9